Table 2. Serious AE reporting with FDA-approved GLP-1RAs.

AE, adverse event; GLP-1RA, glucagon-like peptide-1 receptor agonist

Generic name	Brand name	Mean age (year)	Female sex	Reported by consumers	Reported in the United States
Exenatide	Byetta	60 (11)	58%	62%	58%
Liraglutide	Victoza	59 (12)	56%	35%	50%
Dulaglutide	Trulicity	62 (13)	52%	63%	66%
Liraglutide	Saxenda	47 (13)	81%	44%	41%
Exenatide	Bydureon (BCise)	63 (11)	54%	55%	67%
Semaglutide	Ozempic	59 (14)	60%	51%	58%
Semaglutide	Rybelsus	62 (14)	52%	26%	49%
Semaglutide	Wegovy	48 (13)	78%	47%	58%
Tirzepatide**	Mounjaro	56 (14)	65%	85%	76%
Tirzepatide**	Zepbound	49 (12)	77%	92%	67%
Overall		59 (13)	58%	54%	59%